UY33993A - Análogo macrocíclico de la sangliferina y su método de producción - Google Patents

Análogo macrocíclico de la sangliferina y su método de producción

Info

Publication number
UY33993A
UY33993A UY0001033993A UY33993A UY33993A UY 33993 A UY33993 A UY 33993A UY 0001033993 A UY0001033993 A UY 0001033993A UY 33993 A UY33993 A UY 33993A UY 33993 A UY33993 A UY 33993A
Authority
UY
Uruguay
Prior art keywords
sangliferina
production method
macrocyclic
analog
macrocyclic analog
Prior art date
Application number
UY0001033993A
Other languages
English (en)
Spanish (es)
Inventor
Gregory Matthew Alan
Moss Steven James
Wilkinson Barrie
Original Assignee
Biotica Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1105293.3A external-priority patent/GB201105293D0/en
Priority claimed from GBGB1113629.8A external-priority patent/GB201113629D0/en
Priority claimed from GBGB1202060.8A external-priority patent/GB201202060D0/en
Application filed by Biotica Tech Ltd filed Critical Biotica Tech Ltd
Publication of UY33993A publication Critical patent/UY33993A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
UY0001033993A 2011-03-29 2012-03-29 Análogo macrocíclico de la sangliferina y su método de producción UY33993A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1105293.3A GB201105293D0 (en) 2011-03-29 2011-03-29 Novel compounds and methods for their production
GBGB1113629.8A GB201113629D0 (en) 2011-08-08 2011-08-08 Novel compounds and methods for their production
GBGB1202060.8A GB201202060D0 (en) 2012-02-07 2012-02-07 Novel compounds and methods for their production

Publications (1)

Publication Number Publication Date
UY33993A true UY33993A (es) 2012-10-31

Family

ID=46001313

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033993A UY33993A (es) 2011-03-29 2012-03-29 Análogo macrocíclico de la sangliferina y su método de producción

Country Status (29)

Country Link
US (2) US9139613B2 (enExample)
EP (2) EP2691412B1 (enExample)
JP (2) JP6118792B2 (enExample)
KR (2) KR101911484B1 (enExample)
CN (3) CN103619869B (enExample)
AR (1) AR085724A1 (enExample)
AU (2) AU2012235880B2 (enExample)
BR (2) BR112013024965A2 (enExample)
CA (2) CA2830827C (enExample)
CL (2) CL2013002739A1 (enExample)
CY (2) CY1116318T1 (enExample)
DK (2) DK2691413T3 (enExample)
EA (2) EA023848B1 (enExample)
ES (2) ES2533438T3 (enExample)
HR (2) HRP20150187T1 (enExample)
IL (2) IL228508B (enExample)
JO (1) JO3063B1 (enExample)
MX (2) MX345351B (enExample)
MY (2) MY170618A (enExample)
PH (2) PH12013502016A1 (enExample)
PL (2) PL2691412T3 (enExample)
PT (2) PT2691413E (enExample)
RS (2) RS53964B1 (enExample)
SG (2) SG193569A1 (enExample)
SI (2) SI2691412T1 (enExample)
TW (1) TWI525098B (enExample)
UY (1) UY33993A (enExample)
WO (2) WO2012131377A1 (enExample)
ZA (2) ZA201307149B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011098809A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه
CN103130734A (zh) * 2011-12-01 2013-06-05 上海药明康德新药开发有限公司 一种合成1,2-吗啉盐酸盐的方法
CN105695541B (zh) * 2016-03-10 2019-03-15 苏州华赛生物工程技术有限公司 一种抗生素nvp018中间体的分离纯化方法
KR20180036522A (ko) * 2016-09-30 2018-04-09 (주)나노믹스 스틸벤 유도체 및 그 제조 방법
BR112019009903A2 (pt) 2016-11-18 2019-08-13 Neurovive Pharmaceutical Ab análogo de sangliferina, combinação, composição farmacêutica, e, método para tratamento de um sujeito sofrendo de câncer ou de malignidade de célula-b
CN112410353B (zh) * 2019-08-23 2023-01-24 上海医药工业研究院 一种fkbS基因、含其的基因工程菌及其制备方法和用途
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
PE20240088A1 (es) 2021-05-05 2024-01-16 Revolution Medicines Inc Inhibidores de ras
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR006514A1 (es) 1995-07-04 1999-09-08 Sandoz Ag Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende
US6124453A (en) 1995-07-04 2000-09-26 Novartis Ag Macrolides
RU2427372C2 (ru) 2005-06-17 2011-08-27 Новартис Аг Применение санглиферина для лечения вируса гепатита с
CN101616683A (zh) 2007-01-04 2009-12-30 德比奥法姆股份有限公司 用于治疗Ullrich先天性肌营养不良的非免疫抑制性环孢霉素
JP5789190B2 (ja) 2008-09-24 2015-10-07 シャンハイ インスティテュート オブ オーガニック ケミストリー,チャイニーズ アカデミー オブ サイエンシズ 新規の遺伝子クラスター
CN101691575B (zh) * 2008-09-24 2013-06-05 中国科学院上海有机化学研究所 一种萨菲菌素的生物合成基因簇
WO2011098809A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098805A1 (en) 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
WO2011098808A1 (en) * 2010-02-09 2011-08-18 Biotica Technology Limited Sanglifehrin based compounds
KR101900974B1 (ko) * 2010-12-20 2018-09-21 뉴로바이브 파마슈티컬 에이비 상글리페린 유도체 및 이의 제조 방법
JO3063B1 (ar) * 2011-03-29 2017-03-15 Neurovive Pharmaceutical Ab مركب مبتكر وطرق لانتاجه

Also Published As

Publication number Publication date
MY170618A (en) 2019-08-21
CA2830827A1 (en) 2012-10-04
IL228508A0 (en) 2013-12-31
CA2830831A1 (en) 2012-10-04
EP2691412B1 (en) 2014-12-24
IL228508B (en) 2018-01-31
MY170637A (en) 2019-08-21
KR101868084B1 (ko) 2018-06-18
AU2012235961B2 (en) 2016-09-01
MX345352B (es) 2017-01-26
SG193568A1 (en) 2013-11-29
IL228509A0 (en) 2013-12-31
AU2012235880B2 (en) 2016-11-17
KR20140071958A (ko) 2014-06-12
CA2830831C (en) 2020-03-10
CN103619869B (zh) 2015-11-25
EP2691412A1 (en) 2014-02-05
KR101911484B1 (ko) 2018-10-24
BR112013024974A2 (pt) 2016-09-06
EP2691413A1 (en) 2014-02-05
JO3063B1 (ar) 2017-03-15
JP6118792B2 (ja) 2017-04-26
AR085724A1 (es) 2013-10-23
ZA201307149B (en) 2015-04-29
AU2012235961A1 (en) 2013-10-10
DK2691413T3 (en) 2015-04-07
HK1189237A1 (en) 2014-05-30
SI2691412T1 (sl) 2015-05-29
WO2012131371A1 (en) 2012-10-04
WO2012131377A1 (en) 2012-10-04
PT2691412E (pt) 2015-03-25
JP2014510746A (ja) 2014-05-01
ES2533437T3 (es) 2015-04-10
US9139613B2 (en) 2015-09-22
CY1116318T1 (el) 2017-02-08
PH12013502000B1 (en) 2018-08-10
BR112013024965A2 (pt) 2017-04-18
EA023848B1 (ru) 2016-07-29
CN103635484A (zh) 2014-03-12
JP6118793B2 (ja) 2017-04-26
CN103635484B (zh) 2017-05-10
AU2012235880A1 (en) 2013-10-17
IL228509B (en) 2018-02-28
CL2013002739A1 (es) 2014-07-11
US20140038885A1 (en) 2014-02-06
PL2691413T3 (pl) 2015-05-29
JP2014514290A (ja) 2014-06-19
KR20140057481A (ko) 2014-05-13
MX345351B (es) 2017-01-26
EA201391399A1 (ru) 2014-02-28
CN107417766A (zh) 2017-12-01
ES2533438T3 (es) 2015-04-10
PH12013502000A1 (en) 2013-12-02
PL2691412T3 (pl) 2015-08-31
HRP20150187T1 (xx) 2015-06-05
PH12013502016A1 (en) 2013-12-16
EA023907B1 (ru) 2016-07-29
EA201391396A1 (ru) 2014-02-28
RS53963B1 (sr) 2015-08-31
HRP20150184T1 (hr) 2015-05-08
SI2691413T1 (sl) 2015-05-29
MX2013011043A (es) 2014-04-25
TWI525098B (zh) 2016-03-11
DK2691412T3 (en) 2015-04-07
EP2691413B1 (en) 2014-12-24
ZA201307231B (en) 2015-05-27
CY1116186T1 (el) 2017-02-08
HK1189236A1 (en) 2014-05-30
CN103619869A (zh) 2014-03-05
US20120251581A1 (en) 2012-10-04
TW201300398A (zh) 2013-01-01
CA2830827C (en) 2020-03-10
PT2691413E (pt) 2015-03-25
SG193569A1 (en) 2013-11-29
RS53964B1 (sr) 2015-08-31
US9090657B2 (en) 2015-07-28
MX2013011051A (es) 2014-03-13
CL2013002740A1 (es) 2014-07-11

Similar Documents

Publication Publication Date Title
UY34278A (es) Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
MX345351B (es) Compuesto macrociclico y metodos para su produccion.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
AR089993A1 (es) Macrociclos peptidomimeticos
DOP2014000043A (es) Pirimidinas anilladas sustituidas y uso de las mismas
PE20160841A1 (es) Macrociclos como inhibidores del factor de coagulacion (fxia)
UY36544A (es) Derivados de 4h-pirrol[3,2-c]piridin-4-ona
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
EA201691194A1 (ru) Стимуляторы ргц
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CO6351786A2 (es) Inkibidores de la cinasa map p38
UY33467A (es) Compuestos pyrazolo[1,5-a]pirimidinas para tratamiento antiviral del virus sincicial respiratorio humano, sus composiciones y métodos de producción.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
ECSP11011258A (es) Pirimidinas fusionadas
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
PH12016500250B1 (en) Novel triazolo [4,5-d] pyrimidine derivatives
ECSP13013008A (es) Imidazopiridazinas como inhibidores de quinasa akt
PH12016501699A1 (en) 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one derivatives and their use as antibacterial agents
SG10201900541QA (en) Derivatives of xanthone compounds
DOP2009000285A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulacion sanguinea.
CL2018003610A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina.
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
CO2020001506A2 (es) Nuevos compuestos

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20210804